[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
作者信息
Czownicki Z, Utracka-Hutka B
出版信息
Nowotwory. 1981;30(4):377-83.
PMID:6792599
Abstract
摘要
相似文献
1
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Nowotwory. 1981;30(4):377-83.
2
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.美司钠（2-巯基乙烷磺酸钠）作为尿路保护剂在接受进一步氮杂磷类化疗的出血性膀胱炎患者中的疗效。
J Clin Oncol. 1987 May;5(5):799-803. doi: 10.1200/JCO.1987.5.5.799.
3
[High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].[大剂量异环磷酰胺疗法：全身使用黏液溶解剂以降低尿路毒性]
Schweiz Med Wochenschr. 1979 Dec 8;109(47):1885-7.
4
Clinical overview of mesna.美司钠的临床概述
Cancer Treat Rev. 1983 Sep;10 Suppl A:175-81. doi: 10.1016/s0305-7372(83)80026-7.
5
[Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
MMW Munch Med Wochenschr. 1979 Jun 1;121(22):760-2.
6
Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
Cancer Treat Rev. 1983 Sep;10 Suppl A:1-192.
7
Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.美司钠预防环磷酰胺所致进一步出血性膀胱炎的疗效。
Med Pediatr Oncol. 1988;16(6):372-4. doi: 10.1002/mpo.2950160603.
8
Cyclophosphamide and ifosfamide: role of uroprotective agents.
Cancer Invest. 1990;8(2):269. doi: 10.3109/07357909009017581.
9
Nursing implications in the administration of ifosfamide and mesna.
Oncol Nurs Forum. 1990 Mar-Apr;17(2):276.
10
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].[美司钠（2-巯基乙烷磺酸钠）对接受氮杂磷类化疗的恶性疾病患儿的影响]
Gan To Kagaku Ryoho. 1990 Mar;17(3 Pt 1):403-6.
Zotero 插件